



Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ
Telephone No. 028 95 36 0333

Medicine Supply Notification: Moviprep® and Plenvu® oral powder sachets
Date of issue: 25/08/2026

[Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

Summary

- Moviprep® oral powder sachets are in limited supply until January 2027.
- Plenvu® oral powder sachets remain available, although intermittent delays in deliveries may be experienced until January 2027.
- Alternative bowel preparations remain available, although their ability to support increased demand is limited.

ACTIONS REQUIRED

Trust pharmacy procurement teams should:

- review local stock holding of all bowel preparations, including stock being held at ward locations and consider centralising stock where appropriate
- liaise with clinical teams to consider switching to Plenvu® where appropriate; although supply is currently constrained, it is expected to be able to support the increased demand until the resupply dates stated
- order Moviprep® and Plenvu® oral powder sachets conservatively from wholesalers and over labelling suppliers in line with projected demands and ordering restrictions in place at the wholesaler
- work with appropriate clinical and diagnostic leads to review use of bowel preparations ensuring:
 - impacted clinical and diagnostic areas are made aware of this shortage and local mitigations;
 - Patient Group Directions (PGDs) are reviewed and updated as required;

Where the above options are not appropriate:

- consider prescribing alternative bowel preparations, taking into account renal function, and other cautions/contraindications, in line with recommendations in the SPCs, and
- ensure the patient is not intolerant to any of the excipients, and is provided with instructions on how to make up and take the bowel preparation (see supporting information below)

Where there is insufficient stock, and clinical judgement determines that a patient should remain on Moviprep® or Plenvu®, liaise with pharmacy services to request urgent supply, facilitated by RPHPS.

Supporting information

Clinical Information

Moviprep® and Plenvu® (macrogol 3350 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate and sodium chloride) are licensed for bowel cleansing before a procedure requiring a clean bowel.

Other bowel preparations include:

- Citramag® effervescent powder sachets
- Citrafleet® oral powder 15.08g sachets
- Picolax® oral powder 16.1g sachets

These preparations contain magnesium and are contraindicated in hypermagnesaemia. They should not be used in patients with severely reduced renal function as accumulation of magnesium in plasma may occur. A low residue diet is recommended with use of these preparations prior to the procedure.

Phospho-soda® 24.4g/10.8g oral solution is a bowel preparation containing sodium dihydrogen phosphate dihydrate and disodium phosphate dodecahydrate. It is contraindicated in patients with renal impairment

Links to further information : SmPC Moviprep® oral powder sachets [MOVIPREP, powder for oral solution - Summary of Product Characteristics \(SmPC\) - \(emc\) | 289](#)

- SmPC Plenvu® oral powder sachets [Plenvu powder for oral solution - Summary of Product Characteristics \(SmPC\) - \(emc\) | 8578](#)
- BNF Moviprep® and Plenvu® oral powder sachets [Macrogol 3350 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate and sodium chloride | Drugs | BNF | NICE](#)
- BNF Citramag® effervescent powder sachets [Citric acid with magnesium carbonate | Drugs | BNF | NICE](#)
- BNF Citrafleet® and Picolax® oral powder sachets [Magnesium citrate with sodium picosulfate | Drugs | BNF | NICE](#)
- BNF Phospho-soda® oral solution [Sodium acid phosphate with sodium phosphate | Drugs | BNF | NICE](#)
- Reducing risk of harm from oral bowel cleansing solutions [\[ARCHIVED CONTENT\] Reducing risk of harm from oral bowel cleansing solutions](#)